RemAb’project has been selected as a CaixaImpulse Consolidate
The Project “RA01: A revolutionary alternative to antibiotics to combat bacterial infectious diseases” is selected by CaixaImpulse Consolidate as one of the leading biomedical projects to make the leap to the market.
- RA01 is an innovative alternative treatment to antibiotics to combat infectious diseases caused by bacteria resistant to antibiotics.
- The project has been selected based on its ability to solve the challenges presented by the search for alternatives to antibiotics to combat infectious diseases.
- The research team has an established company that will start to include patients in its first clinical trial next year.
- This research will also allow the development of a potential treatment for coronavirus infection.
Barcelona March 21st, 2020
The project “RA01 A revolutionary alternative to antibiotics to combat bacterial infectious diseases” has been selected by CaixaImpulse Consolidate as one of the leading projects to leap to the market.
The Research Group led by Dr. Rafael Mañez, from the Institut d’Investigació Biomédica de Bellvitge (IDIBELL) has developed a new therapy (RA01) that allows the selective elimination of specific antibodies.
RA01 is an innovative alternative treatment to antibiotics to combat infectious diseases caused by bacteria resistant to antibiotics.
It can be administered both subcutaneously and intravenously, safely and specifically, eliminating circulating antibodies and preventing the production of new antibodies. It also binds to the B lymphocytes that produce them.
Until now, the elimination of antibodies has been carried out using complex extracorporeal techniques that require immunosuppressive treatments to prevent their return.
The technology of RA01 is based on the temporary elimination of antibodies that are found in many patients and facilitate infections by protecting bacteria from the action of other components of the immune system.
The research project has been recognized by CaixaImpulse Consolidate based on its ability to solve the challenges presented by the search for alternatives to antibiotics to combat infectious diseases, and the value it brings from both a public and economic health point of view. to health systems.
The research team has an established company and is about to include patients for its first clinical trial. The efficacy of the elimination of antibodies with RA01 as anti-infective therapy is based on the existence of antibodies that act as facilitators of infections.
This phenomenon was initially described in viral infections and affects practically all of them, including those caused by coronaviruses.
There is evidence to show in one of the recent coronavirus infections, the MERS-CoV (Middle East Coronavirus), which infects humans from camels, that vaccines under investigation worsen the disease, rather than preventing it.
RemAb Therapeutics is currently collaborating with Al-Imam Mohammad Ibn Saud University in Riyadh, Saudi Arabia to identify and eliminate antibodies that worsen the infection caused by MERS-CoV.
Consequently, the identification and elimination of the antibodies that are likely to facilitate COVID-19 infection constitutes a potential treatment for the disease caused by this virus, and RemAb Therapeutics is already working to develop it as soon as possible.
About RemAb Therapeutics
RemAb Therapeutics, a spin-off of the Bellvitge Biomedical Research Institute (IDIBELL), was created in 2018.
The company is the result of 20 years of research to eliminate specific antibodies through medications.
The investigations began with the objective of eliminating the antibodies responsible for the rejection in the xenotransplantation (transplantation of animal organs). These same antibodies are used by gram-negative bacteria to protect themselves and avoid being destroyed by other components of the immune system.
RA01, the molecule with which clinical trials will begin next year, selectively removes these antibodies and allows the destruction of gram-negative bacteria, including those resistant to antibiotics.
This mechanism of increased antibody infection occurs in all types of infections, including those caused by coronaviruses.
RemAb Therapeutics is working to make the selective elimination of antibodies a new therapy in infectious diseases and other pathologies.